Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes
July 02 2024 - 7:30AM
Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the
“Company”), a pre-clinical-stage pharmaceutical company focused on
the development and commercialization of Telomir-1 as the first
novel small molecule to lengthen the DNA’s protective telomere caps
as a potential treatment for age-related conditions, today
announced that the Company has been added as a member of the
broad-market Russell 3000® and the Russell Microcap® Indexes,
effective July 1, as part of the 2024 Russell indexes
reconstitution.
The annual reconstitution of the Russell US indexes captures the
4,000 largest US stocks as of April 30, ranking them by total
market capitalization. Membership in the Russell 3000® and Russell
Microcap® Indexes, which remains in place for one year, means
automatic inclusion in the large-cap Russell 1000 Index or
small-cap Russell 2000 Index as well as the appropriate growth and
value style indexes. FTSE Russell determines membership for its
Russell indexes primarily by objective, market-capitalization
rankings and style attributes.
“The inclusion of Telomir in the Russell 3000® and the Russell
Microcap® Indexes demonstrates the progress that we have made as a
publicly-traded company since our initial public offering in
February,” said Dr. Chris Chapman, Co-Founder, Chairman, CEO,
President and CMO of Telomir. “Coupled with our recently announced
milestones for our lead product candidate, Telomir-1, we believe
that Telomir is well-positioned to achieve many of our corporate
and clinical objectives in the second half of 2024 and beyond, and
we remain committed developing and commercializing Telomir-1 to
reverse age-related conditions.”
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. According to data as of the end of
December 2023, about $10.5 trillion in assets are benchmarked
against the Russell US indexes, which belong to FTSE Russell, a
prominent global index provider.
For more information about the Russell 3000® Index, the Russell
Microcap® Index and the Russell indexes reconstitution, go to the
“Russell Reconstitution” section on the FTSE Russell website.
To be added to the Telomir Pharmaceuticals email distribution
list, please email telomir@kcsa.com with TELO in the subject
line.
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a
pre-clinical-stage pharmaceutical company focused on the
development and commercialization of Telomir-1 as the first novel
small molecule to lengthen the DNA’s protective telomere caps in
order to potentially reverse age-related conditions. Telomeres are
the protective end caps of a chromosome made up of DNA sequences
and proteins. As humans age, telomeres shorten, with metal
reactivity accelerating the process, which presents us with an
increased chance of contracting a number of degenerative and
age-related diseases. Telomir’s goal is to develop and
commercialize Telomir-1 (which is proposed to be dosed orally) for
a broad range of age-related inflammatory conditions such as
osteoarthritis.
The Nobel Assembly at Karolinska Institute (Sweden) awarded the
Nobel Prize in Physiology or Medicine in 2009 for the discovery of
how chromosomes are protected by telomeres and the enzyme
telomerase.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTSThis press release contains
forward-looking statements, including statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements may be identified by words
such as "aims," "anticipates," "believes," "could," "estimates,"
"expects," "forecasts," "goal," "intends," "may," "plans,"
"possible," "potential," "seeks," "will," and variations of these
words or similar expressions that are intended to identify
forward-looking statements. Any such statements in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements. These forward-looking statements
include, without limitation, statements regarding completion,
timing and anticipated size of the initial public offering and the
expected commencement of trading on the Nasdaq.
Any forward-looking statements in this press
release are based on Telomir's current expectations, estimates and
projections only as of the date of this release and are subject to
a number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the potential use of
the data from our studies, our ability to develop and commercialize
Telomir-1 and the aging process and safety of Telomir-1. These and
other risks concerning Telomir's programs and operations are
described in additional detail in its Annual Report on Form 10-K
for the fiscal year ended December 31, 2023, which is on file with
the SEC. Telomir explicitly disclaims any obligation to update
any forward-looking statements except to the extent required by
law.
For further information, please contact:KCSA
Strategic Communications Phil Carlsontelomir@kcsa.com
Telomir Pharmaceuticalsinfo@Telomirpharma.com(813) 864-2558
Telomir Pharmaceuticals (NASDAQ:TELO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Telomir Pharmaceuticals (NASDAQ:TELO)
Historical Stock Chart
From Aug 2023 to Aug 2024